What is the fair value of LLY?

Based on inv-AI’s institutional-grade analysis, the 12-month fair value estimate for Eli Lilly and Company (LLY) is $920 (range: $782–$1058). Confidence level: HIGH.

Is LLY overvalued or undervalued?

Eli Lilly and Company (LLY) is rated Fairly Priced (Mid) by inv-AI. The current price is $903 versus a mid fair value of $920, implying +1.9% upside.

What is the LLY price target for 2026?

inv-AI’s 2026 fair value range for Eli Lilly and Company (LLY) is $782 (bear) to $1058 (bull), with a base case of $920.

Eli Lilly and Company (LLY) Valuation

Rating: Fairly Priced (Mid)

12-Month Fair Value: $782 – $920 – $1058

Confidence: HIGH

Eli Lilly is the undisputed leader of the GLP-1 revolution. Tirzepatide generated $36.5B in FY2025, and the 2026 guidance of $80-83B implies 25% growth at a ~$1T market cap. The pipeline is best-in-class with orforglipron (oral GLP-1, FDA Q2 2026) and retatrutide (triple agonist). However, at 30x forward earnings, the stock is priced for near-perfect execution with limited margin of safety.

View full report | All intelligence | Home